Real-World Data Show Regorafenib on Par With TAS-102 in Metastatic CRC Real-World Data Show Regorafenib on Par With TAS-102 in Metastatic CRC

A real-world comparison finds similar overall survival in patients with refractory metastatic CRC treated with either regorafenib or trifluridine/tipiracil (TAS-102).Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news